R. F. Clark

Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases.

P. Wiedeman, J. Trevillyan, K. Marsh, 1998, Current pharmaceutical design.

A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies

M. Konopleva, T. Penning, Y. Tong, 2019, Leukemia.

Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity

A. Hoerauf, D. Kempf, S. Ward, 2019, PLoS neglected tropical diseases.

From Bacterial Genomes to Novel Antibacterial Agents: Discovery, Characterization, and Antibacterial Activity of Compounds that Bind to HI0065 (YjeE) from Haemophilus influenzae

P. Hajduk, K. Comess, Liping Yu, 2007, Chemical Biology and Drug Design.

CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1

T. Penning, Y. Tong, J. Leverson, 2014 .

Structure‐based Optimization of MurF Inhibitors

David D. Anderson, P. Hajduk, K. Longenecker, 2006, Chemical biology & drug design.

Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors.

K. Longenecker, T. Penning, Y. Tong, 2021, ACS medicinal chemistry letters.